Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients.  Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure.  The conference was held March 20-22, 2023 in Boston, Mass.  

The study, titled “Persistent Pressure-Volume Dissociation During CardioMEMS Monitoring,” compared volume and pressure in heart failure (HF) patients who underwent CardioMEMS implantation to measure pressure, and direct measurement of total blood volume using Daxor’s blood volume analysis (BVA) diagnostic.   Veraprapas Kittipibul M.D., lead investigator of the study concluded, “Less than half of patients had concordant pressure-volume changes during CardioMEMS monitoring.  Universal volume-directed interventions (i.e. diuretics) in HF patients with high pressures might not be appropriate and should be discouraged.”